BOARD OF DIRECTORS
Chairman and Managing Director
Mr. Jacky Zhang is the founder of Beroni Group. He has gained extensive strategic management, planning and marketing experience in the biotechnology sector. He holds a bachelor's degree in Biotechnology from Tianjin University of Commerce, an MBA from Nankai University, and an MSC in International Management from the University of Sussex. He recently graduated with an EMBA from Tsinghua University. Mr. Zhang and his team have formulated an international development strategy for Beroni Group, including the international development of science and technology, integration with capital markets and globalization.
Mr. Zhang has previously worked in different roles including Head of Human Resources, Project Manager of R&D, CEO Asia Pacific Region, and Executive Director for companies based in China and the UK. He has a special interest in collaborating with global research institutions on bioscience and clinical R&D, as well as technology transfer and new product development. He has been instrumental in developing Beroni Group since incorporation, winning various title recognition programs such as “Tianjin Patent Pilot Unit”, “National Small and Medium-sized Enterprise of Science and Technology”, “Tianjin High and New Technology Enterprise”, “National High and New Technology Enterprise”, “Tianjin-Eagle Enterprise” and “China Market Credit Enterprise”.
He also holds the following positions:
• Guest Professor, Institute of Emerging Economic Industries, China Academy of Management Science
• Expert Member of High-level Talents
• Executive Director, Healthcare Professional Committee, SIFIA
Mr. Zhang adheres to the management philosophy of “people-oriented, mutual respect, sincere cooperation, common development, the pursuit of excellence, global win-win”. Through joint efforts by Mr. Zhang and his management team, Beroni Group has attained a number of significant achievements, and has become a multinational biotechnology enterprise with international team of management and scientists.
Executive Director and CFO
Mr Wong is a Chartered Accountant by profession and has more than 30 years of financial services' experience spanning several countries - England, Hong Kong (China), Malaysia, China and Australia. He started his professional career with Deloitte England and PWC Hong Kong, and later held senior positions in Citibank, HK Stock Exchange, HK Telecom, Hong Leong Group (Malaysia) and Shanghai Pudong Development Bank. He had served as a director or CFO of a few listed companies in Australia. He has obtained a BSc degree from the University of Manchester, England and a MBA degree from Henley Business School, England.
One of the founders of Tianjin Beroni Biotechnology Co., Ltd. After graduating with a business management bachelor degree from the Capital University of Economics and Business, Mr Huang has worked for a world top 500 company for approximately 15 years and was responsible for commodity import and export and international and domestic trade business. He has extensive international trade experience and more than 10 years of experience in business franchising and e-commerce business planning, implementation and team building.
Independent Non-Executive Director
Dr. Richard Buchta has 30 years of experience in product development in pharmaceuticals and vaccines as well as in manufacturing and business development. He has developed and led project teams in the development of over 50 products, of which 25 have been launched in Australia and USA with 12 patents. Richard has worked at both local and multinational pharmaceutical companies including Websters, Wyeth, Astra Zeneca, Stiefel and GSK. He is also a director of Formulytica Pty Ltd, a company providing R&D CRO services in skincare and topical/injectable pharmaceuticals and biologics. Richard is a part-time Senior Lecturer for the Masters of Biotechnology course at the University of Melbourne.
Richard obtained a BSc (HONS) from Monash University, a PhD from Weizmann Institute of Science and University of Trieste, and an MBA (Technology) from Deakin University. He was also a post-doctoral Fellow at the Department of Immunology, John Curtin School of Medical Research, Australian National University.
Mr Guo obtained financial management degree from Henan University. He has 20 years of experience in cold-chain logistics particularly in areas of infrastructure planning, construction, fund raising, resource allocation and implementation. He has also gained rich experience in team building, training and management.
Dr Zhinan yin
Independent Non-Executive Director
Dr. Zhinan Yin graduated from Hubei Medical University in 1984 and finished his Master’s Degree in immunology from Shanghai Second Medical University in 1988. He later obtained his Doctorate degree from the Free University of Berlin in 1997, and his academic dissertation won the Excellent Paper Award. Dr. Yin is a current Dean, Professor and PhD Tutor at Biomedical Translational Research Institute of Jinan University and Visiting Professor at Yale University School of Medicine. He has gained rich experience in the academic world in both US and China. He has over 30 years of working experience with a range of universities including Yale University, Nankai University and Jinan University.
Dr. Yin’s main research area is the differentiation and development of γδT cells and their roles in the regulation of tumor immunity, hepatitis, and intestinal flora. He has published 103 academic articles, among which he is the first author, communication author, or co-corresponding author for 52 academic articles.
Board Secretary & Non-Executive Director
Mr Nicholas Ong has served in the Australian Securities Exchange for seven years as Principal Advisor, overseeing the admission of more than 100 listed companies. He runs a boutique corporate advisory firm in Perth, Western Australia and is also a director or company secretary to a few listed companies in Australia. He holds a Bachelor of Commerce and a MBA from the University of Western Australia.
Dr John Chiplin
Dr. John Chiplin, is the Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc (LSE: N4P) and Scancell Holdings plc. (LSE: SCLP). Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO. From 2012 to 2014, he was President and Chief Executive Officer of Polynoma, a Phase III cancer vaccine company, and from 2006 to 2009 he was Chief Executive Officer of Arana Therapeutics. Prior to this, Dr. Chiplin was head of the ITI Life Sciences investment fund in the UK, where he managed significant negotiations regarding funding with Government Ministers. He had been influential in various other transactions including Intrexon's acquisition of Medistem, Cephalon's acquisition of Arana Therapeutics, and GlaxoSmithKline's acquisition of Domantis. He also serves on several boards including Kings Arms Yard VCT plc and US private company Batu Biologics. Dr. Chiplin received his bachelor and doctorate degrees in Pharmaceutical Science from The University of Nottingham, U.K. Dr Chiplin is based in San Diego, California and London, UK.